Journal of Virology, June 2001, p. 5433-5440, Vol. 75, No. 11
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.11.5433-5440.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Feline Immunodeficiency Virus Cell Entry
Susan C. S.
Frey,1
Edward A.
Hoover,2 and
James I.
Mullins1,3,*
Departments of
Microbiology1 and
Medicine,3 University of Washington,
Seattle, Washington, and Department of Pathology, Colorado
State University, Fort Collins, Colorado2
Received 3 November 2000/Accepted 14 March 2001
 |
ABSTRACT |
The process of feline immunodeficiency virus (FIV) cell entry was
examined using assays for virus replication intermediates. FIV subtype
B was found to utilize the chemokine receptor CXCR4, but not CCR5, as a
cellular receptor. Zidovudine blocked formation of late viral
replication products most effectively, including circular DNA genome
intermediates. Our findings extend the role of CXCR4 as a primary
receptor for CD4-independent cell entry by FIV.
 |
TEXT |
The lentivirus feline
immunodeficiency virus (FIV) infects a broad range of cell types,
including CD4+ and CD8+ T lymphocytes, B
lymphocytes, and macrophages, and analogous to human immunodeficiency
virus (HIV) infection of humans, often results in the progressive loss
of CD4+ T cells and the eventual development of
immunodeficiency in infected cats (2, 9, 21). HIV
infection of T lymphocytes involves attachment of the viral envelope
glycoprotein to the specific cellular receptor CD4 (5,
14). However, this is usually not sufficient to confer
susceptibility to HIV infection (4, 17), and HIV requires
a member of the chemokine receptor family as a coreceptor (6, 7,
11). FIV does not utilize CD4 for entry (12, 18).
However, FIV subtype A viruses adapted for growth in the feline CrFK
cell line utilize CXCR4 as a receptor (23; B. J. Willett, M. J. Hosie, J. C. Neil, J. D. Turner, and J. A. Hoxie, Letter, Nature 385:587, 1997). Human U87
cells expressing CXCR4 supported the formation of syncytia when
infected with FIV Petaluma and FIV Glasgow-8 (30), but no
productive infection was detected. Additionally, recent work indicates
that at least some primary FIV isolates use CXCR4 for cell entry
(26). In this study, we examined the receptor requirements
and viral DNA replication intermediates of FIV. Based on
characteristics common to all retroviruses, including genomic
organization and the process of reverse transcription (8),
we developed a cell entry assay for FIV. The product of reverse
transcription that is preferentially integrated into the host
chromosome to establish a productive infection is a linear DNA molecule
that begins with a 5' long terminal repeat (LTR) and ends with a 3' LTR
(3). However, two circular forms of unintegrated viral DNA
are also found in the nucleus and serve as markers of a productive
infection (3, 28), those containing either one or two
copies of the viral LTR. FIV subtype A, B, and C entry was examined
through the detection of early (LTR), intermediate (LTR-Gag), and late (circular) DNA products of reverse transcription. Like subtype A, FIV
subtype B utilized the chemokine receptor CXCR4 for cell entry, whereas
FIV-C did not enter these target cells at detectable levels. Subtype C
viruses are rare, but subtype B viruses have a wide distribution and
have been identified in Italy, the United States, Canada, Japan, and
Germany (1, 22).
FIV 34TF10 entry into CrFK cells.
Infection of CrFK cells with
subtype A FIV 34TF10 was monitored over time by PCR amplification of
viral genome fragments that represented early, intermediate, and late
stages of the reverse transcription process (Table
1 and Fig.
1). The virus stock was generated by
transfection of the 34TF10 plasmid into CrFK cells, with the
supernatants being combined, filtered (0.45-µm-pore-size), aliquoted,
and stored at
80°C prior to use at a final dilution of 70 50%
tissue culture infective doses.
-actin gene amplification was
included as a control for DNA quantitation and PCR efficiency, using
primers designed as described previously (27) to amplify from both feline and human DNA. The
-actin PCR products were ~600
bp for human and ~1,000 bp for feline products. PCR (reagents and
protocols from Bioline, Reno, Nev.) cycling parameters included denaturation for 3.5 min at 94°C, followed by 35 cycles of 45 s
at 94°C, 45 at 55°C (or 58°C for the LTR primer set or 50°C for
the
-actin primers), and 1 min at 72°C (the final incubation was
for 10 min). The PCR product that represented an early product of
reverse transcription was the LTR fragment, amplified with the LTR-F
and LTR-R primers (Table 1 and Fig. 1). The intermediate product was
the LTR-Gag fragment, amplified with the LTR-F and GAG-R primers, and
the late product was the circle junction fragment, amplified with the
ENV-F and GAG-R primers. These amplifications were carried out using
the cell lines, virus stocks, and PCR controls shown in Table
2 as targets.


View larger version (86K):
[in this window]
[in a new window]
|
FIG. 1.
CrFK cell infection with FIV 34TF10 and detection of
viral replication intermediates. (A) CrFK cells were infected
with FIV 34TF10 in replicate wells and harvested from one well at
0, 6, 20, 30, 45, and 70 h PI. PCR was performed as described in
the text, with FIV 2542-CRFK cellular DNA (FIV+) as the positive
control and H2O plus reagents (H2O) as the
negative control. The DNA marker is a 100-bp or 1-kb ladder, as
indicated. PCR products were separated by agarose gel electrophoresis
and visualized by ethidium bromide staining. (B) Schematic
representation of primer positions for derivation of PCR products in
FIV-infected cells derived from linear and circular viral DNA is shown.
(C) One-LTR circle junction fragment homology (shaded segments) is
indicated. As shown at the bottom of panel C, the fragments produced
after FIV 34TF10 infection were colinear with that expected from the
FIV 34TF10 genome.
|
|
The sensitivity of each primer set was determined using serial
dilutions of p34TF10 and/or a plasmid containing the circle junction
fragment. The threshold for detection of the 163-bp LTR product was 100 copies, and the threshold was 10 copies for the 542-bp
LTR-gag and 967-bp circle junction products (data not
shown). LTR and LTR-gag products were present at 6 h
postinoculation (PI) (Fig. 1A) and became progressively stronger during
the course of the experiment. The circle junction product was detected
at 45 h PI and became stronger with time. Consistent
-actin
levels were found at 6, 20, 30, and 45 h PI, with lower levels
present at 0 and 70 h. This experiment shows that early and
intermediate products are detected soon after infection of CrFK cells
with FIV 34TF10 but that circular products are not detected until
between 30 and 45 h PI.
FIV 34TF10 one-LTR circle junction structure.
Putative FIV
circle junction DNA from CrFK cells infected with FIV 34TF10 was PCR
amplified, cloned, sequenced, and identified as a one-LTR circle
junction (Fig. 1C). A faint product most likely corresponding to a
two-LTR circle junction was also detected in the PCR products analyzed.
Our results are consistent with studies of HIV type 1 (HIV-1) infection
that showed that the two-LTR form is less abundant than the one-LTR
form in tissue culture (10, 20).
Lack of FIV DNA in viral stocks.
Detection of LTR
products early in infection could be due to new synthesis of viral DNA
upon cell entry or to incomplete viral transcripts carried in the FIV
particle (16). The DNase treatment we employed would
eliminate DNA present in the supernatant but not from within the viral
particle. We therefore examined viral inocula for the presence of viral
DNA. Peripheral blood mononuclear cell (PBMC) viral stocks were derived
by coculture of PBMC from uninfected cats and specific-pathogen-free
capture cats infected with FIV field isolates 2546 (FIV-A) or 2542 (FIV-B) (1). CrFK-grown subtype A and B viruses were
derived from chronically infected CrFK cells infected by coculture with
supernatant from FIV-positive PBMC cultures. An equivalent amount of
virus, quantitated using p24 antigen, was used for each infection. PCR
on the viral inoculum did not result in detectable product (Fig.
2A); hence, the PCR signal detected in
the entry assay could be not be attributed to DNA present in the viral
inoculum. Consistent with our results, less than 1% of the HIV-1 (
)
single-stranded DNA found in infected cells can be attributed to DNA
carried into the cell inside the viral particle (25).

View larger version (79K):
[in this window]
[in a new window]
|
FIG. 2.
Lack of FIV DNA in viral stocks and impact of AZT on the
production of viral DNA intermediates. (A) Viral inocula were examined
for the presence of viral DNA by PCR. Viral stocks corresponded to
FIV-A grown in CrFK cells (AC), FIV-B grown in CrFK cells (BC), FIV-B
grown in PBMC (BP), FIV-C grown in PBMC (CP), and FIV 34TF10
(34) grown in CrFK cells. FIV+ corresponds to a positive
control (FIV-infected CrFK DNA). (B) CrFK cells were infected with FIV
34TF10 in replicate wells, differing only by the addition of AZT-1MP.
Cells were harvested at 0, 24, 72, and 144 h and immediately lysed and
stored for subsequent DNA extraction. PCR was performed using 50 ng of
DNA as a template. PCRs were separated by agarose gel electrophoresis
and visualized by ethidium bromide staining (10 µl per sample). The
marker (MW) for the LTR and LTR-gag fragments was a 100-bp
ladder and for the circle and -actin fragments was a 1-kB ladder.
Controls were H2O plus reagents (H2O), CrFK DNA
(CrFK), FIV 34TF10-infected CRFK DNA (FIV+), and p34TF10.
|
|
AZT blocked circle formation in CrFK cells infected with
34TF10.
We monitored the production of viral DNA following FIV
34TF10 infection of CrFK cells in the presence of zidovudine (AZT-1MP) (Sigma; A6806; 10 µg/ml), a nucleoside analogue inhibitor of reverse transcription, or Dulbecco's modified Eagle's medium alone as a
control (Fig. 2B). For the experiments shown in Fig. 2B and 3, cells were seeded with
2× AZT-1MP or Dulbecco's modified Eagle's medium alone and incubated
for 1 h to allow cells to convert AZT to the triphosphate form.
Prior to infection, viral stocks were DNase I treated and filtered
(15). The LTR fragment was present at 0 h PI and the
signal increased with time for all samples (Fig. 2B). The intensity of
the LTR-gag product also increased over time in untreated
cells but was less intense, especially at later time points, for the
AZT group. Circle junction products were detected by 72 h PI in
the untreated sample but were not detected for the AZT-treated group up
to 144 h PI. Our results were consistent with previous studies
showing that inhibitors of reverse transcription are most effective
against long products of reverse transcription (24, 25, 29,
31).


View larger version (150K):
[in this window]
[in a new window]
|
FIG. 3.
AZT can block circle formation in CrFK and U87-T4-CXCR4
cells infected with CrFK-derived FIV-A or FIV-B. FIV subtype A or FIV
subtype B was used to infect CrFK, U87-T4, U87-T4-CCR5, and
U87-T4-CXCR4 cell lines in replicate wells differing only by the
addition of AZT. Cells were harvested, and viral sequences were PCR
amplified and visualized as described in the legend to Fig. 2. The
figure depicts the LTR PCR (A), the LTR-Gag PCR (B), the circle
fragment PCR (C), and the -actin PCR (D). The PCR for each fragment
was performed concurrently for all four cell lines. Four controls were
included for each amplification and were run in lane 2 (PCR CNTL) of
the four gels in each panel, with the first gel of each panel
containing the H2O control, the second gel containing the
CrFK control, the third gel containing the 34TF10 CrFK control, and the
fourth gel containing the 34TF10 plasmid. AC, FIV-A grown in CrFK
cells; BC, FIV-B grown in CrFK cells.
|
|
FIV-B utilizes CXCR4 for entry and AZT blocks circle
formation.
We next sought to determine whether CrFK cell
line-adapted FIV with envelope sequence subtype B, as with subtype A
(23, 30; Willett et al., letter), used CXCR4 for viral
entry (Fig. 3). We infected CrFK, U87-T4, U87-T4-CCR5, and U87-T4-CXCR4
cell lines with FIV subtype A or B virus and monitored the production of viral DNA in replicate wells in the presence of AZT or medium alone.
Chemokine receptor expression was verified by staining with
fluorescently labeled antibodies specific for CXCR4 (12G5 CXCR4-PE) or
CCR5 (2D7 CCR5-FITC) prior to infection (Pharmingen, San Diego, Calif.)
(27). Fluorescein isothiocyanate- and phycoerythrin-mouse immunoglobulin G2a kappa-isotype control antibodies G155-178-FITC and
G155-178-PE (PharMingen) were used as controls for nonspecific binding.
Cells were then analyzed by cytofluorometry using a FACScan flow
cytometer and CellQuest software (Becton Dickinson
Immunocytometry Systems). To show that the CCR5-expressing cell
line was functional and competent for viral infection, we infected the
U87-T4-CCR5 cell line with simian immunodeficiency virus isolate 239 (SIV-239), and the resulting supernatant tested positive for SIV
antigen (p27) at days 10 and 14 PI (data not shown). Cells were
harvested at 0, 24, 72, and 144 h PI and immediately lysed and
stored for subsequent DNA extraction and PCR amplification. Cells were
harvested for the 0-h time point and lysed after exposure to virus
within 10 min. However, this brief exposure of cells to virus resulted in the production of reverse transcription products detectable at
0 h PI in some samples. The LTR (Fig. 3A) and LTR-Gag (Fig. 3B)
PCR products were detected for both of the viral subtypes in CrFK and
U87-T4-CXCR4 cells but not in the U87-T4 or U87-T4-CCR5 cells. AZT
partially inhibited formation of both the LTR and LTR-Gag fragments in
CrFK and U87-T4-CXCR4 cells. Differences were also evident between the
susceptible cell lines, as products were present at 0 h in CrFK
but not in U87-T4-CXCR4 cells. The PCR signal was stronger for the
samples without AZT than for those incubated with AZT for both cell
lines and both viral subtypes. The signal for CrFK cells increased with
time, while infected U87-T4-CXCR4 cells showed a strong and continuing
signal beginning at 24 h PI. Circle formation was detected only
in the absence of AZT and was detected earlier in the U87-T4-CXCR4
cells than in the CrFK cells for both the FIV-A and FIV-B infections
(Fig. 3C). The signal for the
-actin fragment was consistent
overall (Fig. 3D). This experiment demonstrates that early and
intermediate viral DNA products are formed in permissive cells even in
the presence of AZT but that late viral DNA products are only formed at
appreciable levels in permissive cells in the absence of AZT.
FIV-B antigen production in CXCR4-transfected cells.
We
observed the production of syncytia by day 12 of the FIV-B 2542 infection (~10/well) in U87-T4-CXCR4 cells, massive cytopathic effects and many large floating syncytia were present on day 13 (~90/well), and the cultures were terminated due to cytopathic efects
on day 14 (data not shown). This demonstrated that FIV subtype B can
utilize CXCR4 for cell entry and demonstrated productive infection of
FIV-B in U87-T4-CXCR4 cells.
FIV antigen production corresponds to circle formation during FIV
infection.
We next determined if productive FIV infection, as
indicated by the presence of FIV p24 Gag antigen, corresponded to
circle formation during FIV infection (Fig.
4). Viruses were used to infect CrFK,
U87-T4, U87-T4-CCR5, and U87-T4-CXCR4 cell lines. Cellular DNA and
culture supernatants were harvested on days 10 and 17 PI. The cellular
DNA was used for PCR and the culture supernatants were tested for FIV
antigen using the FIV PetChek enzyme-linked immunosorbent assay kit
(Idexx Laboratories, Westbrook, Maine). The samples positive for p24
antigen were the same ones in which circular viral DNA was detected
(Fig. 4). The PBMC-derived subtype B and C FIVs were negative for both
viral DNA intermediates and antigen in the cell lines tested. We did
not observe circle formation or FIV antigen for any of our experiments
that used PBMC-derived FIV-B or FIV-C, indicating that the block to
replication in cell lines is not overcome by the transfection of CXCR4
alone. Most primary isolates of FIV infect PBMC, but only subsets have
been adapted to infect CrFK cells, including the FIV-B PBMC-derived virus used in this study. It is not clear why some primary isolates grown only in PBMC, such as the FIV-C PBMC-derived virus used in this
study, cannot efficiently be adapted to grow in CrFK cells, given that
CrFK cells have been shown to express CXCR4 mRNA (30) and
some primary isolates have been shown to use CXCR4 for entry (26). It may be that some FIV strains use a receptor other
than CXCR4, but when they are adapted to grow in CrFK cells, the
receptor usage switches to CXCR4 in a manner parallel to HIV adaptation for growth in T-cell lines. All three CrFK-derived viruses tested (FIV-A, FIV-B, and 34TF10) were positive for both circle formation and
viral antigen when infecting CrFK or U87-T4-CXCR4 cells but not U87-T4
or U87-T4-CCR5 cells. The only exception was that FIV 34TF10 was
positive for circle formation in the U87-T4-CXCR4 cells, but viral
antigen was not detected (although p24 was detected in other
experiments [data not shown]). The presence of HIV-1 circles has been
suggested to be a molecular indicator of the disease progression of
HIV-1 (13, 32). Hence, the assessment of circle formation
as a predictor of FIV disease progression could be evaluated using the
procedures described here for future studies.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 4.
FIV antigen production corresponds to circle formation
during FIV infection. Lysed cells and supernatants were examined at
days 10 and 17 PI. (A) Circle and -actin fragment PCR results from
days 10 and 17 PI. The positive control was 34TF10 CrFK DNA and the
negative control was an H2O reagent control. The PCR
controls were run in lane 2 (PCR CNTL), with the H2O
reagent control on the top gel for each fragment and the positive
control on the bottom gel for each fragment. The DNA marker was the
1-kb ladder. (B) Results from the enzyme-linked immunosorbent assays
for FIV antigen. T4, U87-T4 cells; R5, U87-T4-CCR5 cells; X4,
U87-T4-CXCR4 cells. Virus designations are defined in the legend to
Fig. 2.
|
|
 |
ACKNOWLEDGMENTS |
The entry assay was adapted to the FIV system with helpful advice
from Edward Clark and Patricia Polacino (University of Washington, Seattle, Wash.). We thank Luis Giavedoni (Southwest Foundation for
Biomedical Research, San Antonio, Tex.) for his continued support and
for the gift of the SIV-239 viral stock. We thank Vida Hodara and Laura
Parodi (Southwest Foundation for Biomedical Research) for assistance
with the SIV work, Aniko Fekete (University of Washington) for
assistance with DNA sequencing, and Maria Velasquillo (Southwest
Foundation for Biomedical Research) for assistance with the flow
cytometry experiments. We thank James Hoxie (University of
Pennsylvania, Philadelphia, Pa.) for the gift of the 12G5 antibody, Candace Mathiason-DuBard (Colorado State University, Fort Collins, Colo.) for preparation of the FIV stocks, Dan Littman (New York University Medical Center, New York, N.Y.) for the gift of the U87 cell
lines, and Tom North (University of Montana, Missoula, Mont.) for the
gift of the CrFK cells.
This work was supported by Public Health Service grants CA59042 (to
J.I.M.) and AI33773 to (E.A.H.).
 |
FOOTNOTES |
*
Corressponding author. Mailing address: Department of
Microbiology, Health Sciences Center, I264, University of Washington, Seattle, WA 98195-7472. Phone: (206) 616-1851. Fax: (360)
838-9259. E-mail: jmullins{at}u.washington.edu.
 |
REFERENCES |
| 1.
|
Bachmann, M. H.,
C. Mathiason-Dubard,
G. H. Learn,
A. G. Rodrigo,
D. L. Sodora,
P. Mazzetti,
E. A. Hoover, and J. I. Mullins.
1997.
Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades.
J. Virol.
71:4241-4253[Abstract].
|
| 2.
|
Brown, W. C.,
L. Bissey,
K. S. Logan,
N. C. Pedersen,
J. H. Elder, and E. W. Collisson.
1991.
Feline immunodeficiency virus infects both CD4+ and CD8+ T lymphocytes.
J. Virol.
65:3359-3364[Abstract/Free Full Text].
|
| 3.
|
Cara, A., and M. S. Reitz, Jr.
1997.
New insight on the role of extrachromosomal retroviral DNA.
Leukemia
11:1395-1399[CrossRef][Medline].
|
| 4.
|
Clapham, P. R.,
D. Blanc, and R. A. Weiss.
1991.
Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus.
Virology
181:703-715[CrossRef][Medline].
|
| 5.
|
Dalgleish, A. G.,
P. C. Beverley,
P. R. Clapham,
D. H. Crawford,
M. F. Greaves, and R. A. Weiss.
1984.
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
Nature
312:763-767[CrossRef][Medline].
|
| 6.
|
Deng, H.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R. E. Sutton,
C. M. Hill,
C. B. Davis,
S. C. Peiper,
T. J. Schall,
D. R. Littman, and N. R. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[CrossRef][Medline].
|
| 7.
|
Dragic, T.,
V. Litwin,
G. P. Allaway,
S. R. Martin,
Y. Huang,
K. A. Nagashima,
C. Cayanan,
P. J. Maddon,
R. A. Koup,
J. P. Moore, and W. A. Paxton.
1996.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
Nature
381:667-673[CrossRef][Medline].
|
| 8.
|
Elder, J. H., and T. R. Phillips.
1993.
Molecular properties of feline immunodeficiency virus (FIV).
Infect. Agents Dis.
2:361-374[Medline].
|
| 9.
|
English, R. V.,
C. M. Johnson,
D. H. Gebhard, and M. B. Tompkins.
1993.
In vivo lymphocyte tropism of feline immunodeficiency virus.
J. Virol.
67:5175-5186[Abstract/Free Full Text].
|
| 10.
|
Farnet, C. M., and W. A. Haseltine.
1991.
Circularization of human immunodeficiency virus type 1 DNA in vitro.
J. Virol.
65:6942-6952[Abstract/Free Full Text].
|
| 11.
|
Feng, Y.,
C. C. Broder,
P. E. Kennedy, and E. A. Berger.
1996.
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science
272:872-877[Abstract].
|
| 12.
|
Hosie, M. J.,
B. J. Willett,
T. H. Dunsford,
O. Jarrett, and J. C. Neil.
1993.
A monoclonal antibody which blocks infection with feline immunodeficiency virus identifies a possible non-CD4 receptor.
J. Virol.
67:1667-1671[Abstract/Free Full Text].
|
| 13.
|
Jurriaans, S.,
A. de Ronde,
J. Dekker,
M. Cornelissen, and J. Goudsmit.
1995.
Increased number of single-LTR HIV-1 DNA junctions correlates with HIV-1 antigen expression and CD4+ cell decline in vivo.
J. Med. Virol.
45:91-98[Medline].
|
| 14.
|
Klatzmann, D.,
E. Champagne,
S. Chamaret,
J. Gruest,
D. Guetard,
T. Hercend,
J. C. Gluckman, and L. Montagnier.
1984.
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
Nature
312:767-768[CrossRef][Medline].
|
| 15.
|
Kootstra, N. A.,
B. M. Zwart, and H. Schuitemaker.
2000.
Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G1 phase of the cell cycle.
J. Virol.
74:1712-1717[Abstract/Free Full Text].
|
| 16.
|
Lori, F.,
F. di Marzo Veronese,
A. L. de Vico,
P. Lusso,
M. S. Reitz, Jr., and R. C. Gallo.
1992.
Viral DNA carried by human immunodeficiency virus type 1 virions.
J. Virol.
66:5067-5074[Abstract/Free Full Text].
|
| 17.
|
Maddon, P. J.,
A. G. Dalgleish,
J. S. McDougal,
P. R. Clapham,
R. A. Weiss, and R. Axel.
1986.
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
Cell
47:333-348[CrossRef][Medline].
|
| 18.
|
Norimine, J.,
T. Miyazawa,
Y. Kawaguchi,
K. Tomonaga,
Y. S. Shin,
T. Toyosaki,
M. Kohmoto,
M. Niikura,
Y. Tohya, and T. Mikami.
1993.
Feline CD4 molecules expressed on feline non-lymphoid cell lines are not enough for productive infection of highly lymphotropic feline immunodeficiency virus isolates.
Arch. Virol.
130:171-178[CrossRef][Medline].
|
| 19.
|
Olmsted, R. A.,
V. M. Hirsch,
R. H. Purcell, and P. R. Johnson.
1989.
Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses.
Proc. Natl. Acad. Sci. USA
86:8088-8092[Abstract/Free Full Text].
|
| 20.
|
Pauza, C. D.,
J. E. Galindo, and D. D. Richman.
1990.
Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells.
J. Exp. Med.
172:1035-1042[Abstract/Free Full Text].
|
| 21.
|
Pedersen, N. C.,
E. W. Ho,
M. L. Brown, and J. K. Yamamoto.
1987.
Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.
Science
235:790-793[Abstract/Free Full Text].
|
| 22.
|
Pistello, M.,
G. Cammarota,
E. Nicoletti,
D. Matteucci,
M. Curcio,
D. Del Mauro, and M. Bendinelli.
1997.
Analysis of the genetic diversity and phylogenetic relationship of Italian isolates of feline immunodeficiency virus indicates a high prevalence and heterogeneity of subtype B.
J. Gen. Virol.
78:2247-2257[Abstract].
|
| 23.
|
Poeschla, E. M., and D. J. Looney.
1998.
CXCR4 is required by a nonprimate lentivirus: heterologous expression of feline immunodeficiency virus in human, rodent, and feline cells.
J. Virol.
72:6858-6866[Abstract/Free Full Text].
|
| 24.
|
Polacino, P. S.,
H. A. Liang,
E. J. Firpo, and E. A. Clark.
1993.
T-cell activation influences initial DNA synthesis of simian immunodeficiency virus in resting T lymphocytes from macaques.
J. Virol.
67:7008-7016[Abstract/Free Full Text].
|
| 25.
|
Quan, Y.,
L. Rong,
C. Liang, and M. A. Wainberg.
1999.
Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1.
J. Virol.
73:6700-6707[Abstract/Free Full Text].
|
| 26.
|
Richardson, J.,
G. Pancino,
R. Merat,
T. Leste-Lasserre,
A. Moraillon,
J. Schneider-Mergener,
M. Alizon,
P. Sonigo, and N. Heveker.
1999.
Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus.
J. Virol.
73:3661-3671[Abstract/Free Full Text].
|
| 27.
|
Rottman, J. B.,
E. B. Freeman,
S. Tonkonogy, and M. B. Tompkins.
1995.
A reverse transcription-polymerase chain reaction technique to detect feline cytokine genes.
Vet. Immunol. Immunopathol.
45:1-18[CrossRef][Medline].
|
| 28.
|
Teo, I.,
C. Veryard,
H. Barnes,
S. F. An,
M. Jones,
P. L. Lantos,
P. Luthert, and S. Shaunak.
1997.
Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS.
J. Virol.
71:2928-2933[Abstract].
|
| 29.
|
Trono, D.
1992.
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses.
J. Virol.
66:4893-4900[Abstract/Free Full Text].
|
| 30.
|
Willett, B. J.,
L. Picard,
M. J. Hosie,
J. D. Turner,
K. Adema, and P. R. Clapham.
1997.
Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses.
J. Virol.
71:6407-6415[Abstract].
|
| 31.
|
Zack, J. A.,
A. M. Haislip,
P. Krogstad, and I. S. Chen.
1992.
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.
J. Virol.
66:1717-1725[Abstract/Free Full Text].
|
| 32.
|
Zazzi, M.,
L. Romano,
M. Catucci,
G. Venturi,
A. De Milito,
P. Almi,
A. Gonnelli,
M. Rubino,
U. Occhini, and P. E. Valensin.
1997.
Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression.
J. Med. Virol.
52:20-25[CrossRef][Medline].
|
Journal of Virology, June 2001, p. 5433-5440, Vol. 75, No. 11
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.11.5433-5440.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.